PharmaMar Announces New Advances in Oncology at ASCO 2015

PharmaMar announces that it will present several clinical studies to showcase the data obtained in various tumor types, including SCLC, soft tissue sarcoma and mesothelioma during the 51st American Society of Clinical Oncology meeting in Chicago (ASCO; May 29-June 2). Abstracts have been selected for oral presentation, poster discussion session and general poster presentation. The studies presented by the Company will include the first-in-class drug YONDELIS® (trabectedin), and the second-generation of this class, PM1183 (lurbinectedin). PM1183 is an inhibitor of the transcriptional machinery and a DNA repair complex, which have proven to be crucial in different tumor types, including SCLC, soft tissue sarcoma and ovarian cancer. In addition, these drugs have been shown to have an effect on the tumor microenvironment by targeting tumor-associated macrophages, which is relevant for cancers such as mesothelioma and ovarian cancer, in which chronic inflammation seems to be a hallmark of the disease. (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b ) (Logo: http://photos.prnewswire.com/prnh/20150203/727958-a ) "PharmaMar continues to advance cancer care through the development of innovative anticancer drugs that target tumors in a way that no one is doing. We are identifying new ways to tackle the root of the disease, and our new class of drugs shows efficacy even in difficult-to-treat tumors, such as small cell lung cancer, mesothelioma and soft tissue sarcoma," says Nadia Badri, MD, VP Medical Affairs, PharmaMar. "The events that will take place this year are crucial for PharmaMar as we move forward in the oncology arena, and this forum is theperfect scenario to feature our clinical programs." Meeting abstracts are available at http://abstracts.asco.org/ Studies highlighted at ASCO 2015 YONDELIS® (trabectedin) Interim data for trabectedin in soft tissue sarcoma, as well as clinical results in mesothelioma will be presented in 4 studies in oral and poster presentations. SAR-3007: A Randomized Phase 3 Study of Trabectedin (T) or Dacarbazine (D) for the treatment of patients (pts) with Advanced Liposarcoma (LPS) or Leiomyosarcoma (LMS). (Abstract 10503) - sponsored by Janssen Products Oral Abstract Session: Sarcoma Presentations (3:00 PM - 6:00 PM). Monday, Jun 1 at 4:00 PM - 4:12 PM at S504 Lead Author: George Demetri, MD et al. Dana-Farber Cancer Institute, Boston, MA, USA. OVC-3006: A Phase 3 Study of Trabectedin (T) plus Pegylated Liposomal Doxorubicin (PLD) versus PLD for Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer. (Abstract TPS5606) - sponsored by Janssen Products General Poster Session: Gynecologic Cancer. Saturday, May 30 from 1:15 PM - 4:45 PM at S Hall A Poster Board 163b Lead Author: Robert L. Coleman, MD The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Activity and Safety of Trabectedin in Patients with Sarcomatoid/Biphasic Malignant Pleural Mesothelioma. (MPM) (Abstract 7561) - sponsored by MaNGO General Poster Session: Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers. Monday, June 1 from 8:00 AM to 11:30 AM at S Hall A Poster Board 309 Lead Author: Diego Luigi Cortinovis, MD Università degli Studi di Milano-Bicocca, Monza, Italy. Time to secondary resistance (TTSR) after rechallenge with trabectedin (T) in myxoid round cell liposarcoma (MRCLPS) patients. (Abstract #10566) General Poster Session: Sarcoma. Sunday, May 31 from 8:00 AM to 11:30 AM at S Hall A Poster Board 210 Lead Author: Roberta Sanfilippo, MD Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. PM1183 (lurbinectedin) Two PharmaMar-sponsored studies will be featured at ASCO. Data from the clinical trial of PM1183 in SCLC will be further highlighted at a Poster Discussion Session that will be followed by time for networking with panelists. Lurbinectedin (PM01183) with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC). (Abstract #7509) General Poster Session: Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers. Monday, June 1 from 8:00 AM to 11:30 AM at S Hall A Poster Board 256 This poster will be discussed at the Poster Discussion Session on Monday, June 1 from 1:15 PM - 2:30 PM at E Hall D2 Lead Author: Martin Forster, MD University College Hospital, London, UK. A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors. (Abstract #TPS2604) General Poster Session: Trial in progress - developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics. Saturday, May 30 from 8:00 AM to 11:30 AM at Poster Board 318b Lead Author: Mariano Provencio Pulla, MD PhD Hospital Universitario Puerta de Hierro, Madrid, Spain.